anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
The emerging field of nanotechnology has paved the way for revolutionary advancements in drug delivery systems, with nanosystems emerging as a promising avenue for enhancing the therapeutic potential and the stability of various bioactive compounds. Among these, cannabidiol (CBD), the non-psychotropic compound of the Cannabis sativa plant, has gained attention for its therapeutic properties. Consequently, researchers have devoted significant efforts to unlock the full potential of CBD's clinical benefits, where various nanosystems and excipients have emerged to overcome challenges associated with its bioavailability, stability, and controlled release for its transdermal application. Therefore, this comprehensive review aims to explain CBD's role in managing acute inflammatory pain and offers an overview of the state of the art of existing delivery systems and excipients for CBD. To summarize this review, a summary of the cannabinoids and therapeutical targets of CBD will be discussed, followed by its conventional modes of administration. The transdermal route of administration and the current topical and transdermal delivery systems will also be reviewed. This review will conclude with an overview of in vivo techniques that allow the evaluation of the anti-inflammatory and analgesic potentials of these systems.
BACKGROUND: Most published reports on SAMD9L-related ataxia-pancytopenia syndrome (ATXPC) have emphasized the hematologic findings. Fewer details are known about the progression of neurologic manifestations and methods for monitoring them.
CASES: We present six individuals from two families transmitting a heterozygous variant in SAMD9L, exhibiting clinical variations in their hematologic and neurologic findings. Serial motor function testing was used to monitor motor proficiency over a 2 to 3 year period in the proband and his father from Family 1.
CONCLUSIONS: Our case series focuses on the neurologic progression in patients with heterozygous variants in SAMD9L. Patients with ATXPC should be followed to evaluate a wide range of neurologic manifestations. Serial motor function testing using a standardized method is helpful to track changes in balance and coordination in children and adults with ATXPC and could aid in a future extended natural history study.
The invention relates to medicine and can be used for developing agents and methods to be used in toxicological practice and by population at home for preventing and reducing risks of dangerous diseases such as intoxication by alcohol substitutes and toxic components of alcoholic beverages. The invention is based on the use of known chemical compounds in the form of vicinal dithioglycoles. They are used for new purposes, namely for developing medicinal agents, the properties of which make it possible to prevent, treat or reduce speed of pathological processes generated by alcohol substitute intoxication. The inventive agents reduce or block the pharmacological effects of alcohols and the derivatives thereof, i.e. produce a direct effect on pathogenetic mechanisms of intoxication development. Said agents are most efficient when perorally administered. Experimental data items proving that the inventive agents and the preventing method, which consists in taking the agents before and after drinking low-quality alcohol-containing beverages and alcohol substitutes, can be widely used in future are also disclosed. The use of the invention makes it possible to reduce the number of intoxication cases produced by substitutes, to decrease the severity of intoxication and the toxic effect of alcoholic beverages consumed at home.
PCT No. PCT/FR96/00261 Sec. 371 Date Sep. 12, 1997 Sec. 102(e) Date Sep. 12, 1997 PCT Filed Feb. 16, 1996 PCT Pub. No. WO96/26284 PCT Pub. Date Aug. 29, 1996The invention teaches modified desmin enhancer sequences which yield high level expression of operably linked DNA sequences. The claimed modified desmin enhancer sequences may be operably linked to genes encoding a protein. Further these modified desmin enhancer sequences may be placed into vectors including plasmids and transformed into cells including bacteria or myoblasts. Finally, these modified desmin enhancers may be used in methods of expression of proteins in the transformed bacteria or myoblasts.
Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in the EN3835-201 study, will be eligible for this study. The study will consist of up to two evaluations approximately 3 years after the first dose of study drug was received in the EN3835-201 study.
PURPOSE:To obtain an agent for preventing axillary odor suppressing sweating by astrictive action, effectively restricting axillary odor, inexpensively obtainable and producible, having high safety to human body, readily usable by simple treatment, comprising alum as a main component. CONSTITUTION:An agent for preventing axillary odor comprising potassium alum or aluminum alum or an alum such as calcined burnt alum prepared by removal of water of crystallization from these alums under heating as a main component. The alum can form an agent for preventing axillary odor by itself alone, optionally mixed with other stable components in response to necessity of handling such as ready application, processed into liquid, creamy or powdery state and used. When the agent is used, underarm is cleaned by bathing, etc., and the agent is applied. In the case of creamy state, the agent is used with an applicator or fingers, in the case of liquid, the agent is impregnated into cotton, etc., and then applied to underarm by coating. In order to maintain inhibitory effects on axillary odor, preferably the agent is applied after bathing every day.
For the Control group, after receiving education and brochures, the 'Nottingham Functional Foot Care Diagnostic Form' and 'Diabetic Foot Evaluation Form' were completed at the 1st, 2nd, and 3rd months. Similar to the Intervention group, new wound formation, wound classification, and healing status of existing ulcers were monitored for this group as well.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the development of medicinal agent sodium diclofenac. Agent is made as a tablet covered by envelope containing sodium diclofenac, aerosil A-300, potato starch, calcium stearate, collidone CL-M, microcrystalline cellulose taken in the definite ratio of components. The tablet core is covered by enterosoluble envelope prepared from an aqueous suspension comprising collicute MAE 100P, collidone-30, ferric oxide (III), propylene glycol, talc, titanium dioxide taken in the definite ratio of components. Invention proposes also method for preparing anti- -inflammatory agent. Invention provides good decomposition owing to qualitative and quantitative ratio of components. EFFECT: improved preparing method, valuable properties of agent. 2 cl
Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
STUDY OBJECTIVES: Rapid eye movement sleep behavior disorder (RBD) is strongly associated with phenoconversion to an overt synucleinopathy, e.g. Parkinson's disease (PD), Lewy body dementia, and related disorders. Comorbid traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD)-henceforth "neurotrauma" (NT)-increase the odds of RBD by ~2.5-fold and are associated with an increased rate of service-connected PD in Veterans. Thus, RBD and NT are both independently associated with PD; however, it is unclear how NT influences neurological function in patients with RBD.
METHODS: Participants ≥18 years with overnight polysomnogram-confirmed RBD were enrolled between 8/2018 to 4/2021 through the North American Prodromal Synucleinopathy Consortium. Standardized assessments for RBD, TBI, and PTSD history, as well as cognitive, motor, sensory, and autonomic function, were completed. This cross-sectional analysis compared cases (n = 24; RBD + NT) to controls (n = 96; RBD), matched for age (~60 years), sex (15% female), and years of education (~15 years).
RESULTS: RBD + NT reported earlier RBD symptom onset (37.5 ± 11.9 vs. 52.2 ± 15.1 years of age) and a more severe RBD phenotype. Similarly, RBD + NT reported more severe anxiety and depression, greater frequency of hypertension, and significantly worse cognitive, motor, and autonomic function compared to RBD. No differences in olfaction or color vision were observed.
CONCLUSIONS: This cross-sectional, matched case:control study shows individuals with RBD + NT have significantly worse neurological measures related to common features of an overt synucleinopathy. Confirmatory longitudinal studies are ongoing; however, these results suggest RBD + NT may be associated with more advanced neurological symptoms related to an evolving neurodegenerative process.
Patients with heart failure with preserved ejection fraction (HFpEF) are characterized by exercise intolerance and premature fatigue during physical activity. An abnormal exercise pressor reflex mediated by neural feedback from mechano- and/or metabosensitive group III and IV muscle afferents may contribute to these debilitating symptoms. However, little is known about the role and relative contribution of group III/IV afferents in circulatory control and fatigue development in patients with HFpEF. By studying both patients with HFpEF and well-matched controls, the investigators will evaluate the contribution of these muscle afferents to circulatory control and fatigue development, factors recognized to be major contributors to exercise intolerance. The investigators will use lumbar intrathecal fentanyl to block the central projection of group III/IV muscle afferents during voluntary and passive exercise (no concomitant effect on feedforward drive). This proven approach will enable us to evaluate, and distinguish between, the effects of group III and IV muscle afferents on central and peripheral hemodynamics during exercise, the exercise-induced development of central and peripheral fatigue (femoral nerve stimulation techniques), and on exercise tolerance. The investigators will also study muscle morphometry, baroreflex and chemoreflex sensitivity, and investigate intramuscular metabolic changes of the quadriceps during exercise using 31phosphorus magnetic resonance spectroscopy to evaluate disease-related alterations in cardiovascular reflex sensitivity and intrinsic muscle characteristics as a potential factor determining alterations in circulatory control and fatigue resistance in patients with HFpEF. Finally, the investigators will repeat these studies after a supervised 12-week knee-extension exercise training program, allowing us to investigate the effect of chronic exercise on the role of group III/IV muscle afferents in the hemodynamic response to exercise, the development of fatigue, and, ultimately, exercise tolerance. If this project confirms a significant contribution of group III/IV muscle afferents to the exercise intolerance exhibited by patients with HFpEF, and that chronic exercise can alleviate these impairments, the proposed work will provide the scientific basis for a paradigm shift in the treatment of this growing population.
Use of cross-linked polyvinylpyrrolidone as a deaggredating agent in tablets contg. a dispersion of griseofulvin in polyethylene glycol is new. The presence of cross-linked PVP not only improves the speed of disintegration in the digestive fluids but insures rapid dissolution of the griseofulvin. Pref. tablets contain 20-25% w/w of PVP. They may be made by dry or wet granulation.
CARNEXIV can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Pregnancy registry and epidemiological data demonstrate an association between the use of carbamazepine during pregnancy and congenital malformations, including spina bifida and malformations involving other body systems (e.g., craniofacial defects and cardiovascular malformations). There have been postmarketing reports of developmental delays based on neurobehavioral assessments. 

Pregnancy registry data suggest that, compared with monotherapy, there may be a higher prevalence of teratogenic effects associated with the use of anticonvulsants in combination therapy.

In animal studies, administration of carbamazepine during pregnancy resulted in developmental toxicity, including increased incidences of fetal malformations.

If CARNEXIV is used during pregnancy, or if the patient becomes pregnant while taking CARNEXIV, the patient should be informed of the potential risk to the fetus.
Long-term or even permanent neuropsychological impairments are frequently observed after aneurysmal subarachnoid hemorrhages (aSAH). Among the most common impairments after aSAH are memory deficits. Volumetric MRI studies suggest an association of memory dysfunctions with temporal atrophy, especially of the hippocampus. In a previous study, 77 patients with good or moderate clinical outcome after aSAH were examined one year after discharge (Bendel et al., 2006). Temporomesial atrophy was detected without direct brain damage, e.g. by secondary ischemia. Due to the effects of complex cognitive impairments on the quality of life and participation in social and professional life, this relationship will be examined in more detail in the planned study. Specifically, we will investigate to what extent the frequently observed discrepancy between severe memory impairment and normal structural imaging results (no focal lesions in temporomesial areas) is due to hippocampal atrophy. In contrast to Bender and colleagues, this question will be investigated in the acute phase of the disease, immediately after admission to inpatient neurological rehabilitation.

Over a period of 24 months, 29 neurological rehabilitation patients with aSAH (Hunt \& Hess grade I and II) are going to be included. Within the first week (day 1 to 7) after study enrollment, a native MRI examination (without contrast agent) is performed, in which a high-resolution 3D-MPRAGE sequence (T1 weighting) is measured in the sagittal plane. After checking the data quality of the 3D-MPRAGE sequence, especially with regard to its suitability for hippocampal volume determination, a comprehensive neuropsychological examination is performed, in which specific memory and attentional functions are tested.
Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Bacterial vaginosis not diagnosed according to Nugent score (\<7).
Used exclusively by the organizers to retrain the top-ranking 5 AI algorithms, with large-scale data. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021.
G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
Apatinib + GD regimen. For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after. For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles. Apatinib monotherapy is then maintained until 1 year following complete resection.
Procedure for the preparation of new organic salts of penicillins, characterized in that they are considered separately or in combination A) the free penicillins are combined with an amino acid (amino acid) or a derivative thereof, for example, an ester or an amide, in the presence of water and/or an organic solvent, for example, ether, chloroform, amino acetate, etc. The combination thus formed is separated by evaporation of the aqueous layer, or by simple filtration when the formed combination is separated in the course of the reaction. B) the penicillins are reacted directly on the amino acids in alkaline reaction (example: arginine). C) the sodium and/or potassium salts of penicillins are directly reacted on the hydrochlorides of the amino acids (example: histidine hydrochloride). D) the amino acids in acid reaction are previously converted into esters (example: leucine methyl ester) or amides (example: glycinamide). (Machine-translation by Google Translate, not legally binding)
Patients will be submmitted to combined acute physical exercises (strength and aerobic) that consist on: supine, paddling, leg press 45º, knee extensor, flexor knee (two sets of 15 to 20 repetitions, with loads between 30% and 40% of a maximum repetition, with 30 seconds of interval). We will perform in the first exercise for upper and lower limbs, for heating, after starting the training where 4 series of 8 to 12 maximum repetitions will be performed, using the load between 70% and 80% of 1 maximum repetitions, already evaluated. The recovery between sets will be 90 seconds and between exercises will be 120 seconds.
PURPOSE:To obtain a cosmetic having good feeling of use and stability, presenting effects of skin-beauty and skin-conditioning such as strongness, gloss, smoothness and fresh-looking, etc., in applying to skin, containing skin-beauty component having remedy action of wound, by mixing aloenin, etc. CONSTITUTION:Aloenin expressed by the formula and/or salt of the aloenin obtained by extraction from Aloe in Liliaceae is contained as an active ingredient and mixed a water-soluble polymeric material having >=2,000 molecular weight, such as polypeptide, as necessary to obtain the aimed cosmetic. Aloenins expressed by said formula is white, non-odor powder and readily handled and excellent in mixing properties and solubility to other cosmetic components and capable of applying to all type of agent. Mixing fraction of the aloenins is 0.005-5wt.% of total cosmetic. In extraction of the aloenin expressed by the formula, dried leaf of plant of Aloe, etc., Aloe arborescenes Mill. var. natalensis Berger is roughly clashed, extracted twice by water or organic solvent and purified with a resin column to afford the aloenin expressed by the formula having high purity of 95-99%.
Compositions containing a carrier and microbubbles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope formed of at least one base lipid and at least one emulsifying agent. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 ml oxygen/dl suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs. The microbubbles may be administered alone or in combination with other treatments as an adjunctive therapy.
Patients receive abemaciclib PO BID on days 1-28. Patients with tumors that are hormone receptor positive also receive and anastrozole or letrozole per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Views of obesity as a consequence of "lack of willpower" or other behavioral choices, rather than a complex array of biological and other factors, are quite common among undergraduate students. Many undergraduates in prenursing or biology programs have little exposure to the physiology and pathophysiology of obesity, including learning about leptin and other hormones involved in appetite control. I developed materials for teaching about the pathophysiology of obesity in two different pathophysiology courses: one designed as a survey of pathophysiology topics for prenursing majors, and the other designed as an in-depth exploration of the molecular and cellular basis of selected diseases for upper-division biology majors. In the molecular basis of disease course, obesity is covered as part of a unit organized around metabolic syndrome. The discussion includes molecular and cellular mechanisms that link obesity to several other diseases, including type 2 diabetes and atherosclerosis. This article briefly describes the approaches I have taken for teaching obesity to two different undergraduate student populations and lists several resources that may be useful tools for teaching about obesity.NEW & NOTEWORTHY This article describes approaches for teaching obesity in an allied health major pathophysiology course, and, additionally, in an upper-division biology major course on the cellular and molecular basis of disease.
Once the patient will arrive at the maternity ward with prelabor rupture of membranes, we will wait for spontaneous delivery to occur. After 24 hours of rupture of membranes, the woman will receive oxytocin for augmentation of labor.
Depression is the most frequently detected and preventable mental illness among people with human immunodeficiency syndrome, with rates two to four times higher than in the general population. Currently, depression is estimated to affect 350 million people worldwide. To assess the prevalence of depression and associated factors among HIV/AIDS patients attending antiretroviral therapy clinic at Adama Hospital Medical College, Adama, Central Ethiopia. An institutional-based cross-sectional study was conducted from April 01 to September 30, 2021, at Adama Hospital Medical College, Adama, Ethiopia. A total of 420 individuals were selected using a systematic random sampling technique. After informed consent was obtained from each study participant, data were collected through face-to-face interviews, observations, and document reviews. Subsequently, the data were entered into EPI-Info Version 7 and analyzed by Statistical Package for the Social Sciences version 21. Variables with p-values less than 0.25 in the univariable logistic regression analysis were subsequently included in the multivariable logistic regression analysis to account for potential confounding factors. The association was measured using adjusted odds ratio (AOR) with a 95% confidence interval (CI), and variables with p-values less than 0.05 were considered statistically significant. The prevalence of depression was 52.4% (95% CI 47.6-57.1). Factors significantly associated with depression among HIV-positive patients on antiretroviral therapy included employment status [AOR = 0.22(95% CI 0.13-0.36)], the patient's most CD4 count [AOR = 6.99 (95% CI 2.81-17.38)], duration of months on antiretroviral therapy [AOR = 5.05 (95% CI 2.38-10.74)] and presence of chronic non-communicable diseases [AOR = 7.90 (95% CI 4.21-14.85)]. The highest proportion of HIV-positive patients taking antiretroviral drugs exhibited depression. Employment was identified as a preventive factor, whereas having a low CD4 count, recently initiating antiretroviral therapy, and having chronic non-communicable diseases were associated with increased odds of depression among HIV-positive patients on antiretroviral therapy. There need to strengthen mental health screening and treat depression among HIV-positive patients, particularly by targeting identified factors.